Struggling up stairs with knee pain, or hearing a click when you bend your knee? These common complaints can be linked to localised cartilage wear. This article looks at how the non-surgical ChondroFiller injection may help, and sets realistic expectations throughout.

The Role of Knee Cartilage

Your knee relies on articular cartilage — a smooth tissue covering the ends of the bones — for comfortable, low-friction movement. When it wears in a localised area, the surface becomes irregular, which can produce the clicking or catching sensation many people notice on stairs or when rising from a chair. Unlike bone, cartilage has a very limited natural capacity for self-repair, which is why early assessment matters.

Common Causes and Spotting It Early

Localised cartilage wear can follow a sports injury, a period of joint overload, changes in alignment, or simply the effects of age. It does not always mean arthritis is widespread; in many cases the damage is confined to one surface or one compartment of the knee. Identifying the nature and extent of the wear early — typically with MRI and clinical assessment — helps to determine which treatment options are appropriate, and whether conservative measures alone are sufficient.

How the ChondroFiller Injection Works

ChondroFiller is a Class III CE-marked medical device: a type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals in Germany and used in the UK under prescription. When delivered as an ultrasound-guided injection, the clinician prepares the collagen components at the bedside, and the mixed gel is injected directly into the affected joint. There is no incision, no theatre, and no general anaesthetic.

Once in place, the collagen scaffold self-gels within a few minutes and may settle over the worn surface, providing a structured matrix through which the body's own progenitor cells can migrate and begin to lay down new cartilage-like tissue. The device is acellular — it contains no donor cells — and its biological action depends on recruiting the patient's own repair cells. It is not a cushioning filler in the way hyaluronic acid injections work; it is a regenerative scaffold.

Compared with surgical options such as microfracture or autologous chondrocyte implantation, the ChondroFiller injection is non-surgical, involves minimal downtime, and can be performed in an outpatient setting. It is not a cure for arthritis and does not reverse established joint-space narrowing; it is best suited to localised, contained cartilage defects.

What the Research Tells Us

Published clinical experience with ChondroFiller as an injection is encouraging, though the evidence base continues to develop. In knee studies, International Knee Documentation Committee (IKDC) scores have been shown to improve by approximately 30 points over 12 to 36 months of follow-up, which represents a clinically meaningful change in pain and function. Imaging with MOCART scoring (which assesses cartilage repair tissue quality on MRI) has returned scores of around 80 and above in published series, indicating good defect fill and tissue integration.

A 2023 study in a different joint — the base of the thumb — reported improvements in pain and grip strength following ChondroFiller injection (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U., 2023. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage). This illustrates the versatility of the scaffold, though knee-specific outcomes are what matter most for patients with the symptoms described here.

Individual responses vary. Benefits cannot be guaranteed, and not every patient achieves a meaningful improvement. The available safety record is reassuring: across a large number of units used since the device's introduction, serious adverse events have not been reported in published manufacturer data.

Is It Right for You? What to Expect

The ChondroFiller injection is most likely to suit adults who have localised knee cartilage wear — confirmed on imaging — and who want a non-surgical option before considering more invasive procedures. It is generally less appropriate for people with widespread tricompartmental arthritis, significant joint-space narrowing, or active joint infection.

The procedure is performed under ultrasound guidance as an outpatient. The clinician warms and prepares the collagen gel, the skin is cleaned, and the gel is injected into the joint. Most people return to light activity within a day or two, though full benefit develops gradually over weeks to months as the scaffold integrates and the body's repair response unfolds. A structured loading programme during recovery supports the best outcome.

Conclusion

Clicking and stair pain linked to localised knee cartilage wear can be distressing, but they do not always require major surgery. The ChondroFiller injection offers a non-surgical, outpatient route that may ease symptoms and support the joint in appropriately selected patients — without theatre admission or prolonged downtime. It is not a cure, and realistic expectations are essential.

At London Cartilage Clinic on Harley Street, a specialist assessment will determine whether the ChondroFiller injection, or another pathway, is the most suitable option for your knee. If you would like an evaluation, a consultation can be arranged through the clinic.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.